PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
Read
about PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT
Read
about PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT
PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA
Read
about PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA
Acuitas Therapeutics named one of BC’s Top Employers of 2025
Read
about Acuitas Therapeutics named one of BC’s Top Employers of 2025
PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
Read
about PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles
Read
about PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles
Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
Read
about Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
Read
about Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
Acuitas Therapeutics Honoured With Philanthropic Award
Read
about Acuitas Therapeutics Honoured With Philanthropic Award